Advancing First-in-Class TIL Programs Through Uncertain Regulatory & Quality Expectations for Successful Approvals
- Navigating first time interactions with inexperienced review teams
- Defining and defending potency assays for complex cell products
- Applying quality by design concepts to highly variable therapies